Earn free CPD points
15096
page-template-default,page,page-id-15096,bridge-core-1.0.5,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.0.2,vc_responsive

Earn free CPD points

Dapagliflozin improves outcomes in heart failure patients

In the DAPA-HF trial, SGLT-2i dapagliflozin added to optimal standard therapy in patients with HF with reduced ejection fraction, reduced the risk of worsening HF events, CV death, and improved symptoms.

Why do SGLT-2 inhibitors reduce the risk of heart failure events?

Heart failure, the earliest and most preventable complication of diabetes, and the most treatable – glucose-lowering drugs can affect its progression long before they impact microvascular events.

Cross-talk between the kidneys and circulation in diabetes

New guidelines from the EASD and ADA retain metformin as first-line treatment for T2D. Preferred second-line therapies, however, are now SGLT-2i or GLP-1RA, depending on the presence of/risk for CVD and CKD.

Does it matter how you lower glucose?

Recent evidence of beneficial macrovascular protection from new anti-diabetic drugs has intensified the importance of appropriate strategies to lower glucose in individual diabetes patients.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

People with type 2 diabetes (T2d) are at high risk for adverse cardiovascular (cV) outcomes and progressive decline in renal function.

Diabetes and heart failure

Heart failure and diabetes are closely related, with each conferring a poorer prognosis on the other. Careful consideration of theĀ  glycaemic control agent can help prevent incident heart failure.